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A group of papers investigates functional regulatory elements in genomes from human tissue samples and
cell lines. What can neuroscientists learn from the gigantic data set and how will it affect the direction of
neuroepigenetics?A striking and unexpected conclusion
that emerged from the completion of
the Human Genome Project (Figure 1A)
was that the number of genes in the hu-
man genome is no more than that of
C. elegans (Lander et al., 2001; Venter
et al., 2001). Further, we learned that
over 95% of the human genome exhibits
no protein-coding information. These dis-
coveries shifted our focus from genomes
to epigenomes to explain how the com-
plex variegation of human cells and
tissues may arise from a precise orches-
tration of this limited number of genes.
The modern definition of epigenome is
reversibly encoded information to the
genome without altering the underlying
DNA sequences. The epigenome works
as landmarks for each cell to correctly
interpret the invariable scriptio continua
of DNA-based genome. There are ever-
expanding facets of the epigenome,
each of which requires specific experi-
mental modalities to assess—DNase-
seq for open chromatin, Hi-C for chro-
matin long-range interaction, ChIP-seq
for transcription factor binding or his-
tone post-translational modifications,
and bisulfite-seq for 5-methylcytosine
modifications (Figure 1B). All of the epige-
nomic information is marked on a single
string of genomic DNA, but most epige-
netic studies often pick a subset of epige-
nomic features due to the economical
reason. Thus, the interdisciplinary Ency-
clopedia of DNA Elements (ENCODE)
project was launched to achieve holistic
and comprehensive understanding of hu-
man epigenomes (Figure 1A) (ENCODE
Project Consortium, 2004). Over the last12 Neuron 86, April 8, 2015 ª2015 Elsevier Indecade, the ENCODE project has suc-
cessfully generated a large amount of
epigenomic data from over a hundred
cell or tissue types (ENCODE Project
Consortium, 2012, 2007). Very recently,
the Roadmap Epigenomics Mapping
Consortium had their first large-scale
release, which focused on epigenomes
of human primary cells and tissue sam-
ples, including nine human adult brain
structures (Figure 1C) (Roadmap Epige-
nomics Consortium et al., 2015). Now
there is substantial evidence that epige-
netic regulation is especially crucial for
brain function and the mammalian brain
exhibits a particularly plastic epigenetic
landscape (Guan et al., 2009; Guo
et al., 2011). Here we highlight the
value, application, limitation, and future
of large-scale epigenomic studies from
the viewpoint of the emerging field of
neuroepigenetics.
Since the ENCODE consortium was
launched in 2003, we have experienced
an exponential growth in the epigenome
database. Several major releases have
significantly advanced our understanding
of the human epigenome (Figure 1A).
First, the ENCODE consortium revealed
1% of the human epigenome and tran-
scriptome using microarray technologies
in 2007. This pilot release provided a
number of groundbreaking discoveries
and insights, including the identifica-
tion of pervasive genome-wide transcrip-
tional activity and characterization of
distal regulatory elements and mega-
base-scale chromatin domains (ENCODE
Project Consortium, 2007). Second, the
ENCODE consortium released 30 publi-c.cations with massive data sets in 2012,
which provided a far more comprehen-
sive view of the epigenetic landscape
and additional insights (ENCODE Project
Consortium, 2012). Using 147 cell types
from mostly cultured cell lines, these
studies sought to establish generally
applicable principles of the human epige-
nome, which included a hierarchical
network of transcription factor (TF) bind-
ing, predicting TF binding using known
TF motifs and DNase I footprinting, and
predicting functional chromatin states
by integrating histone modifications and
chromatin accessibility (Figure 1B)
(ENCODE Project Consortium, 2012;
Ernst and Kellis, 2010; Ernst et al.,
2011; Thurman et al., 2012). Third, the
Roadmap Epigenomics Mapping Con-
sortium released an even greater amount
of data focused on human primary cells
and tissues (Roadmap Epigenomics
Consortium et al., 2015), which revealed
more comprehensive and fundamental
epigenetic principles with potential for
widespread biological relevance. For
example, Ziller et al. attributed key tran-
scription factors to regional epigenomic
transition throughout consecutive stages
of in vitro neural differentiation (Ziller
et al., 2015). Gjoneska et al. showed
that epigenome changes in a mouse
Alzheimer disease model occur at
conserved regulatory elements for im-
mune cells (Gjoneska et al., 2015).
Currently, the growth of the epigenome
database derived from these consor-
tiums has three immediate benefits.
First, these large data sets can be probed
for epigenetic marks of interest at specific
1990 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
HGP launched
First human chromosome sequencing completed
draft of human genome
HGP completed
First NGS released
ENCODE project launded
ENCODE 1% pilot project released
Roadmap Epigenomics Mapping project launched
First DNase seq released
First Mnase seq releasedFirst ChIP-seq released
Single molecular sequencer released
First human whole genome bisulfite-seq released
ENCODE project progress released
Roadmap project progress released
A
B
A
N
R
E
P
O
M
D
Na
E
Nb
F
Nc
Tim
e
Histone PTMs
DNA modifications
RNA abundance
TF binding sites
Chromatin
long-range
interaction
NN
N
N
O
NH
2
R
NH
O
H2
N
N
N
N
NH
N
O
N
N
N
N
O
H2
N
N
N
O
NH N
H2
N
N
H2N
O
R
O
O
O
OO
P
O O-
O
OO
P
O O-
NH
N
O
N
N
N
N
O
H2
O
O
O
P
O O-
O O
P
O O-
O
O
O
O
O
O
-
O
O
O
O
O
O
-
O
O
O
O
O
-
O
O
O
O
-
PPPP
Enhancer Heterochromatin Active TSS Strong transcription
Upstream
Downstream
O
p e n chrom
atin
Upstream Downstream
H3K27me3
H3K36me3
H3K4me1
H3K4me2
H3K4me3
H3K9ac
H3K9me3
H3K27ac
H3K14ac
H3K18ac
H3K23ac
H3K4ac
H3K56ac
H3K79me1
H3K79me2
H3K23me2
H3K9me1
H3T11ph
H2AK5ac
H2AK9ac
H2BK120ac
H2BK12ac
H2BK15ac
H2BK20ac
H2BK5ac
H4K20me1
H4K5ac
H4K8ac
H4K12ac
H4K91ac
C
<Chromatin state segmentation>
Ehnancer-Promoter pair
5-hmC/Tet enzyme discovered in mammalian genomes
5-fC/5caC discovered in mammalian genomes
Histone code hypothesis suggested
Figure 1. The Past, Present, and Future of Epigenomic Studies in the Nervous System
(A) The timeline of key discoveries and technical advances in the field of epigenetics. HGP, Human Genome Project; ENCODE, Encyclopedia of DNA Elements;
NGS, Next Generation Sequencer; ChIP, chromatin immunoprecipitation; hmC, 5-hydroxymethylcytosine; fC, 5-formylcytosine; caC, 5-carboxylcytosine;
Mnase, micrococcal nuclease; Tet, Ten-eleven translocation.
(B) Key epigenomic features that current large-scale epigenomic projects uncover. Open chromatin can be assayed by DNase-seq, FAIRE-seq, or ATAC-seq;
chromatin long-range interactions can be assayed by Hi-C; transcription factor (TF) binding sites can be assayed by TF ChIP-seq; RNA abundance can be as-
sayed by RNA-seq; DNA modifications can be assayed by whole-genome bisulfite sequencing; and histone post-translational modifications can be assayed by
histone ChIP-seq (top). Using general principles achieved by large epigenome data sets, chromatin states can be defined based on epigenomic features, such as
chromatin accessibility or histone PTMs (bottom). As such, although each genomic region can have hundreds of epigenomic features requiring hundreds of
epigenetic assays, we only need a minimal set of epigenomic features to define chromatin states.
(C-F) The future of neuroepigenetics. The Roadmap Epigenomics Project distinguished nine brain structures of human brain: angular gyrus, head of caudate nu-
cleus, inferior parietal lobule, inferior temporal gyrus, middle frontal gyrus, midbrain, occipital pole, pons, andmedulla oblongata (C). Each brain region comprises
a variety of distinct cell types, including neurons (N), astrocytes (A), oligodendrocytes (O), microglia (M), blood cells (R), endocytes (E), and pericytes (P) (D). All
these cell types with distinct functions and epigenomes collectively contribute to the epigenome data generated. Thus, it is difficult to know which cell type is the
major contributor for an observed epigenomic transition, or whether the observed epigenomic transition is the result of the epigenome change within each cell
type or the result of changes in the cellular composition of the sample. Each cell type also contains multiple subtypes (E). For example, there are a number of
different neuronal subtypes (denoted as Na, Nb, and Nc) with distinct functions, morphologies, and probably epigenomes. Furthermore, each neuronal subtype
can exhibit differential epigenome over time during development or upon physiological or pathological perturbations (F).
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Previewsloci by individual researchers to guide
their own studies. Second, it allows tar-
geted approaches for genome-wide ana-
lyses. Recent works by Lunnon et al.
and De Jager et al. are excellent examples
of how epigenetic perturbations in human
brain disorders can be identified using
targeted approaches (De Jager et al.,
2014; Lunnon et al., 2014). These studies
employed microarray-based methylation
analysis, which covers only 1.5% of
CpGs in the genome but included
most identified promoters and functional
genomic elements based on previous
genome-wide studies. Designing assays
that could specifically target only func-
tional elements would be a very powerful
tool for large-scale screening of brain-
specific epigenomic perturbations. Third,
we can infer chromatin state information
using only key epigenomic features
(Figure 1B, bottom). The roadmap project
consortium reported that a combination
of a subset of histonemodifications is suf-
ficient to define the nearby transcription
levels and even to impute the chromatin
accessibility and local DNA methylation
levels (Roadmap Epigenomics Con-
sortium et al., 2015). Therefore, if such
an assumption holds true for other tissues
of interest, we can achieve a similar level
of precision as large-scale epigenomic
projects using a fraction of epigenomic
assays.
Is there an endpoint to the trend
of massive data accumulation in epi-
genetics? Clearly, epigenome projects
would not achieve ‘‘completion’’ in the
sameway as the HumanGenome Project.
First, unlike the largely invariable genome,
the epigenome varies along multiple
and interacting dimensions that include
different cell and tissue types, specific
developmental stages, and physiological
or pathological perturbations (Figures
1C–1F). Second, there has been a rapid
expansion of identified epigenetic fea-
tures, such as different DNA base mod-
ifications, hundreds of histone post-
translational modifications and binding
of transcription factors, nucleosome oc-
cupancy, and 3-dimensional chromatin
architectures (Figures 1A and 1B). If
the variability of the epigenome among
tissue and cell types with different devel-
opmental, physiological, or pathological
conditions, combinedwith themyriad fac-
ets of epigenetic features, precludes the14 Neuron 86, April 8, 2015 ª2015 Elsevier Inidentification of all possible reference epi-
genomes, then what is the future of the
epigenome project, especially from the
neuroepigenetics point-of-view?
First, we expect to identify generally
applicable rules defining chromatin states
using a minimal number of epigenetic
features. There are a few tools defining
chromatin features using a subset of his-
tone modifications without bias. More-
over, the Roadmap Epigenomics project
showed the possibility of computing the
distribution of missing epigenetic marks
with precision based on other observed
epigenetic data sets (Ernst and Kellis,
2015). It suggests that certain epigenetic
marks are dependent variables, and
thus not necessary to be assayed for all
biological conditions. Eventually, utilizing
the simplest rules to distinguish the distri-
bution and rearrangement of underlying
chromatin functional segments would
become possible. Second, we expect to
see the emergence of single-cell epige-
nomics to address the heterogeneity
issue (Figures 1C–1F). Heterogeneity is
indeed a very imminent challenge for neu-
roepigenetics (Shin et al., 2014). There
are two types of heterogeneity: cell-
type/static heterogeneity and temporal/
dynamic heterogeneity. Static heteroge-
neity indicates cells with distinct func-
tions, such as neurons and astrocytes,
which are therefore expected to exhibit
distinct basal epigenomes. Dynamic het-
erogeneity indicates a change of the epi-
genome within the same cell population
resulting from changes in activity, a crit-
ical property of dynamic brain circuits
and function (Guo et al., 2011). Static het-
erogeneity can be partially addressed
by cell selection through methods such
as fluorescence-activated cell sorting,
yet these approaches may preclude iden-
tification of unappreciated heterogeneity
among the seemingly homogenous pop-
ulation. Dynamic heterogeneity can only
be tackled by single-cell epigenetic as-
says because of the continuous nature
of the process. Third, we expect to
achieve allelic information of various epi-
genomic features via sequential profiling
of different epigenetic marks in the
same sample, such as Chip-bisulfite
sequencing (Guo et al., 2014). Fourth,
we need to know the causal and temporal
relationships between different epige-
netic marks. These mechanistic insightsc.will be tremendously helpful in under-
standing which epigenomic assay to use
when we study more specific develop-
mental or disease conditions.
Epigenetic mechanisms are emerging
as an important component in human
brain function and dysfunction (De Jager
et al., 2014; Guan et al., 2009; Lunnon
et al., 2014). The mammalian brain also
exhibits unique epigenetic features, such
as high levels of hydroxymethylcytosine
(Kriaucionis and Heintz, 2009) and
nonCpG methylation (Guo et al., 2014).
Moreover, over 90% of disease alleles
are located at non-coding distal regula-
tory elements, suggesting the importance
of epigenetic mechanisms in the brain.
The immense complexity of neural struc-
tures and circuitry, in conjunction with
both static and dynamic heterogeneity of
cellular populations, make it challenging
to understand the mechanisms and con-
sequences of epigenetic modifications.
However, considering the relatively short
history of the large-scale epigenomic
projects and the rapid advancement of
supporting technologies that include
assays for novel epigenomic features,
next-generation sequencing technology,
and bioinformatics makes us optimistic
for the future of neuroepigenetics.
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